Room temperature stable solid vaccine formulations suitable for needle free delivery

无针头输送室温稳定的疫苗，有可能减少给药频率和/或节省抗原含量，一直是疫苗技术的“圣杯”。Glide Pharma公司开发了一种无针设备(最近完成了一期临床研究)，该设备可以提供固体制剂，并唯一地满足所有这三个要求。Glide之前已经证明了用户的接受性和该技术的剂量节约效果。该项目的目的是评估室温稳定性，从理论上讲，与液体制剂相比，固体疫苗更容易实现这一点。Glide可以凭借其无针、稳定和低成本的疫苗技术来革命性地提供疫苗。这将使发达国家能够更好地为大流行局势做好准备，降低医疗成本，使发展中国家能够充分享受现代疫苗的好处。

Needle free delivery of a room temperature stable vaccine which has the potential to reduce dosing frequency and / or to save antigen content has been a 'holy grail' of vaccine technology. Glide Pharma has developed a needle free device (recently completed a Phase 1 clinical study) that can deliver solid formulations and can uniquely meet all three requirements.Glide has previously demonstrated user acceptability and the dose sparing effect of the technology. The aim of this project is to evaluate room temperature stability which, theroretically, should be much easier to achieve with a solid vaccine compared to a liquid formulation.Glide can revolutionise vaccine delivery with its needle free, stable and low cost vaccine technology. This will enable developed countries to be better prepared for pandemic situations and to reduce healthcare costs, and the developing countries to enjoy the full benefits of modern vaccines.